Asian Journal of Biochemistry, Genetics and Molecular Biology

Volume 13, Issue 1, Page 11-19, 2023; Article no.AJBGMB.95970
ISSN: 2582-3698

The Use of Dimethyl Biguanide as a Potential Treatment for Alzheimer's Disease in Rats

Hamed A. Abosharaf [a*], Yasmin Elsonbaty [a], Ehab Tousson [b] and Tarek M. Mohamed [a]

[a] Biochemistry Division, Chemistry Department, Faculty of Science, Tanta University, Tanta-31527, Egypt.
[b] Zoology Department, Faculty of Science, Tanta University, Tanta-31527, Egypt.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/AJBGMB/2023/v13i1283

Open Peer Review History:
This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/95970

Original Research Article

Received: 15/10/2022
Accepted: 30/12/2022
Published: 02/02/2023

ABSTRACT

Amis: Alzheimer's disease (AD) is one of the most rapidly growing diseases in recent times. Despite extensive research to find an appropriate medicine, there has been no effective drug until now.
Study Design: The present study was designated to investigate the therapeutic impact of antihyperglycemic dimethyl biguanide on Alzheimer's disease symptoms.
Methodology: Alzheimer's disease was induced in male rats by $AlCl_3$ and D-galactose at doses of 50 and 120 mg/kg daily for one month. Then, for the next four weeks, rats were given oral dimethyl biguanide (200 mg/kg daily).
Results: The obtained data indicated an increase in the arrival time of the AD rat group (G2) compared to the control group (G1). In addition, the AD rat group showed an elevation in glucose

**Corresponding author: E-mail: hamed_biochemistry@science.tanta.edu.eg;*

level, oxidative stress, liver, and kidney function. Importantly, dimethyl biguanide was able to ameliorate these unpleasant outcomes in G3. Interestingly, dimethyl biguanide was able to reduce GFAB immunoreactivity in the dimethyl biguanide -treated group (G3) compared to the AD group (G2).

Conclusion: In fact, dimethyl biguanide can delay the symptomatology of AD.

Keywords: Dimethyl biguanide; Alzheimer's disease; D-galactose; $AlCl_3$

1. INTRODUCTION

Alzheimer's disease (AD) is a neurological condition that worsens over time and is brought on by hereditary, epigenetic, and environmental factors [1,2]. There are two different types of AD, including the more prevalent late-onset AD and an early-inception AD. Severe memory loss and decreased cognitive function are hallmarks of AD [3]. Furthermore, while the increase of amyloid deposition and neurofibrillary plaques in the brain is considered the most acceptable hypothesis of AD formation, the actual mechanism for the emergence of AD symptoms remains relatively unknown [4]. There are currently no effective therapies for AD [5]. As a result, extensive research is required to study AD pathology and its relationship with other diseases in order to create a complete map of AD pathways that will aid in the development of appropriate medication.

Previous research has found a clear link between diabetes, particularly type 2, and Alzheimer's disease. Moreover, it was reported that insulin levels and the insulin pathway in the brain were impaired in AD patients [6,7]. From this point forward, there is a growing trend surrounding the use of anti-diabetic drugs to treat Alzheimer's disease and mild neurodegenerative symptoms.

Dimethyl biguanide, a member of the biguanide family of antihyperglycemics, is currently the most used for treating type 2 diabetes mellitus (T2DM) [8]. Previous biomedical reports have even shown that dimethyl biguanide has several valuable impacts, including cardiovascular protection, anti-cancer activity, and anti-inflammatory properties [9]. Based on the anti-inflammatory effect of dimethyl biguanide, we and others suggested that it can protect against AD [10,11]. The aim of this study was to investigate the impact of dimethyl biguanide against Alzheimer's disease.

2. MATERIALS AND METHODS

2.1 Chemicals

Dimethyl biguanide, D- galactose were gained from Sigma-Aldrich (St. Louis, MO, USA). $AlCl_3$ was obtained from Loba chemie, India. Calretinin antibody (No. IR627) and polyclonal GFAB (NO. Z0334) were provided by Agilent Dako, Denmark. All other chemicals obtained in highly pure grade.

2.2 Experimental Section

2.2.1 Alzheimer's disease induction design

The current research was performed corresponding to the general guidelines of Faculty of Science, Tanta University Egypt (Approved ethical No. IACUC-SCI-TU-0259) for handling of laboratory animals. 200- 220 g on average, thirty male Wistar rats were bought from Faculty of Pharmacy, Cairo University, Egypt. Rats were maintained according to general care guidelines (free access to water and food *ad libitum*/ 12 h day cycle at 25^0C) [12]. Five groups were generated (n= 10/ each group). G1; is normal rat. G2; is AD rats that received 50 mg/Kg of $AlCl_3$ and 120 mg/ Kg of D- galactose daily for constitutive 4 weeks [13]. G3; Biguanide treated that firstly received $AlCl_3$ and D-galactose as the same as G4 for one month, then treated with 200 mg/Kg dimethyl biguanide for one month [14]. Before the scarification, the memory impairment was checked by the classical labyrinth test [15]. Finally, the rats were slaughtered by decapitation and the skulls were opened with fine scissors and the brains were excised. Hippocampus were quickly removed and divided into two segments; one was fixed in 10% neutral buffer formalin, for histopathological examination and the remaining was washed and stored at -80°C for preparation of tissue homogenates.

2.2.2 Biochemical assessment in serum

Under anesthesia, a blood sample was taken from the eye, and serum was obtained by centrifuging the clotted blood samples. Fasting blood glucose (FBG), liver function [Alanine transaminase (ALT)and Aspartate transaminase (AST)] and kidney function (urea and creatinine) were conducted according to the instruction of commercial kits procured from (Bio diagnostic, Egypt).

2.2.3 Evaluation oxidative and anti-oxidative parameter in hippocampus

Glutathione (GSH) and glutathione peroxidase (GPx) were assessed employing profitable kits from (Bio diagnostic, Egypt). Further, Malondialdehyde (MDA), lipid peroxidation indicator, was measured according to [16].

2.2.4 Histopathological investigation

Brains were excised and fixed in 10% formalin in phosphate buffered saline pH 7.4 for 24 h at 4°C. Fixed tissues were dehydrated through a graded series of ethanol and embedded in paraffin according to standard procedures. Paraffin sections (5µm thick) were mounted on gelatin chromalum–coated glass slides and used for Haematoxylin and eosin stains as a routine method [17].

2.2.5 Glial fibrillary acidic protein (GFAP) immunohistochemistry

Expression of GFAB-ir (GFAB immunoreactivity) in brain sections (hippocampus) were detected using the avidin biotin peroxidase complex method. Briefly, sections were incubated with Polyclonal rabbit anti-GFAP immunoglobulin (Z0334, Dako) [18] at a dilution of 1:1000 for 16 h at room temperature.

2.3 Statistical Analysis

GraphPad Prism v. 6 (GraphPad Software, San Diego, CA, USA) was used in the current study. Using one way ANOVA and multiple comparison the significances between groups were statistically presented. *P*<0.05 was considered as significant.

3. RESULTS

3.1 Dimethyl Biguanide Ameliorate Memory, Glucose Level, Liver Kidney Function in AD Induced Rats

Table 1 indicated that there was a significant increase in the time taken during Labyrinth in the AD-induced rats (G2). This time was clearly reduced in biguanide-treated groups (G3). Furthermore, in G2, liver function, including ALT and AST, and kidney parameters, such as creatinine and urea, were elevated, but improved after Biguanide administration in G3.

3.2 Impact of Dimethyl Biguanide on the Hippocampal Oxidative Stress

Administration of $AlCl_3$ and D-galactose induced oxidative stress in hippocampus with visible decline in antioxidant parameters in G2 compared to control (G1). Indeed, the treated group with dimethyl biguanide showed a magnificent drop in MDA and an elevation of GPx and GSH as antioxidant parameters as shown in Fig. 1.

3.3 Histopathology Assessment

Histopathology examination of hippocampus of treated rats demonstrated a typical structure with tightly packed layers of pyramidal cells in control groups (Fig. 2A). Further, AD-induced rats (G2) revealed oedema, disseminate vacuolar deterioration, vacuolated neurocytes and degenerated, reduction and alteration pyramidal cells (Fig. 2B). On the other hand, dimethyl biguanide treatment rats (G3) showed little tissue damage with a few neuronal injuries without extensive vacuolar atrophy (Fig. 2C).

3.4 Immunohistochemistry of GFAB

GFAB immunoreactivity in AD rats (G2) showed moderately positive immunoreactivity compared to control (G1), which significantly dropped in the dimethyl biguanide post-treatment group (G3) as shown in Fig. 3.

4. DISCUSSION

The current aim of this study is to investigate the curing role of the antidiabetic dimethyl biguanide against Alzheimer's disease. The data collected revealed that the arrival time of AD rats was 3.48 times longer than that of control rats. This high-fold change was dropped after dimethyl biguanide uptake. Moreover, AD rats showed higher glucose levels than the control rats, which were further ameliorated by dimethyl biguanide treatment. Our data agreed with previously published reports, which indicated an elevation in arrival time with hyperglycemia [19-21]. Furthermore, the alteration in liver and kidney functions in AD syndrome was well-known due to

impairment in lipid metabolism with elevated inflammatory markers [22,23]. Our findings were completely consistent with this phenomenon.

Later research found a buildup of free radicals to be involved in the etiology of AD or moderate cognitive impairment [24]. Furthermore, an elevation of the oxidative stress marker MDA, along with a considerably declining antioxidant system (GPx and GSH), were clearly presented in our data. Previously published reports revealed similar findings [25,26].

On the level of histopathology changes, our results indicated a harmful alteration with distortion in the hippocampus region of AD rats that was greatly ameliorated with dimethyl biguanide medication. Previous reports suggested that the brain is shielded from harm by dimethyl biguanide. The findings of our investigation are consistent with these studies [27-30], and we found that the rats' hippocampus significantly reduced the amount of neuronal tissue damage.

In our work, AD model rats showed substantial hippocampus astrogliosis (heightened GFAP intensity with a reduction in calretinin). In these rats, a dose of 200 mg/kg dimethyl biguanide resulted in significant improvement. Our findings are completely in line with those of Pilienko et al. (2020) who indicated that dimethyl biguanide improved GFAB levels in AD rats [31].

Table 1. Impact of dimethyl biguanide on biochemical parameters in AD induced rats

Parameters	Rat groups		
	G1	G2	G3
Arrival time (sec)	43±4.51	150.4±6$^{\#}$	92.3±3.2$^{\#,*}$
FBG (mg/dl)	79.3±1.23	214.23±3.23$^{\#}$	126.2±2.16$^{\#,*}$
ALT (IU)	35.2±2.1	66.72±1.54$^{\#}$	44.3±1.98$^{\#,*}$
AST (IU)	44.3±1.2	98.2±2.3$^{\#}$	65±1.78$^{\#,*}$
Urea(mg/dl)	24.8±2.54	57.2±1.97$^{\#}$	35.4±1.1$^{\#,*}$
Creatinine (mg/dl)	0.8±0.02	2.7±0.1$^{\#}$	1.6±0.13$^{\#,*}$

Data was presented as mean± SD, P<0.05 was considered as significant. #, are the significancy compared to control (G1) and AD group (G2) respectively*



Fig. 1. The antioxidant/ oxidative stress parameters in treated rats. Data was presented as mean± SD, P<0.05 was considered as significant. #,* are the significancy compared to control (G1) and AD group (G2) respectively. GPx: Glutathione peroxidase, GSH: Glutathione, MDA: Malondialdehyde



Fig. 2. Histopathological Changes in hippocampus structure in different groups. A: Control, B: Alzheimer's disease (AD) revealed oedema, disseminate vacuolar deterioration, vacuolated neurocytes (arrows) and degenerated, reduction and alteration pyramidal cells, C: Dimethyl biguanide post-treatment group



Fig. 3. Immunohistochemical Changes in hippocampus structure stained with GFAB in different groups. A: Mild positive reactions (arrows) in Control, B: Moderate positive reactions in Alzheimer's disease (AD) (arrows), C: Mild positive reactions (arrows) in dimethyl biguanide post-treatment group

5. CONCLUSION

Antihyperglycemic dimethyl biguanide was able to improve neural damage caused by Alzheimer's disease and other cognitive disorders. As a result, Alzheimer's disease pathogenesis is more complicated and related to other metabolic disorders, such as diabetes mellitus type 2. More research is needed to determine whether they have the same origin or if they have different pathways.

DISCLAIMER

The products used for this research are commonly and predominantly used products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

ETHICAL APPROVAL

Animal Ethic committee approval has been collected and preserved by the author(s).

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Apter JT, Shastri K, Pizano K. Update on disease-modifying/preventive therapies in Alzheimer's disease. Curr Geriatr Rep. 2015;4(4):312-7.
   DOI: 10.1007/s13670-015-0141-x, PMID 26543800.
2. Uwishema O, Mahmoud A, Sun J, Correia IFS, Bejjani N, Alwan M et al. Is Alzheimer's disease an infectious neurological disease? A review of the literature. Brain Behav. 2022;12(8):e2728.
   DOI: 10.1002/brb3.2728, PMID 35879909
3. Lecanu L, Papadopoulos V. Modeling Alzheimer's disease with non-transgenic rat models. Alzheimers Res Ther. 2013;5(3):17.
   DOI: 10.1186/alzrt171, PMID 23634826.
4. Ali SK, Ali RH. Effects of antidiabetic agents on Alzheimer's disease biomarkers in experimentally induced hyperglycemic rat model by streptozocin. Plos One. 2022;17(7):e0271138.
   DOI: 10.1371/journal.pone.0271138, PMID 35802659
5. Rygiel K. Novel strategies for Alzheimer's disease treatment: an overview of anti-amyloid beta monoclonal antibodies. Indian J Pharmacol. 2016;48(6):629-36.
   DOI: 10.4103/0253-7613.194867, PMID 28066098
6. Gasparini L, Netzer WJ, Greengard P, Xu H. Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol Sci. 2002;23(6):288-93.
   DOI: 10.1016/s0165-6147(02)02037-0, PMID 12084635
7. Knezovic A, Budisa S, Babic Perhoc A, Homolak J, Osmanovic Barilar J. From determining brain insulin resistance in a sporadic Alzheimer's disease model to exploring the region-dependent effect of intranasal insulin. Mol Neurobiol; 2023.
   DOI: 10.1007/s12035-022-03188-5, PMID 36596966
8. Ferrannini E. The target of metformin in Type 2 diabetes. N Engl J Med. 2014;371(16):1547-8.
   DOI:10.1056/NEJMcibr1409796, PMID 25317875.
9. Malínská H, Oliyarnyk O, Škop V, Šilhavý J, Landa V, Zídek V, et al. Effects of metformin on tissue oxidative and dicarbonyl stress in transgenic spontaneously hypertensive rats expressing human C-reactive protein. Plos One. 2016;11(3):e0150924.
   DOI: 10.1371/journal.pone.0150924, PMID 26963617.
10. Sonnen JA, Larson EB, Brickell K, Crane PK, Woltjer R, Montine TJ et al. Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol. 2009;66(3):315-22.
    DOI: 10.1001/archneurol.2008.579, PMID 19139294
11. Beeri MS, Schmeidler J, Silverman JM, Gandy S, Wysocki M, Hannigan CM et al. Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology. 2008;71(10):750-7.
    DOI:10.1212/01.wnl.0000324925.95210.6d , PMID 18765651
12. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE

guidelines for reporting animal research. Plos Biol. 2010;8(6):e1000412.
DOI: 10.1371/journal.pbio.1000412, PMID 20613859

13. Mallikarjuna N, Praveen K, Yellamma K. Role of Lactobacillus plantarum MTCC1325 in membrane-bound transport ATPases system in Alzheimer's disease-induced rat brain. Bioimpacts. 2016;6(4): 203-9.
DOI:10.15171/bi.2016.27, PMID 28265536
14. Zhang S, Xu H, Yu X, Wu Y, Sui D. Metformin ameliorates diabetic nephropathy in a rat model of low-dose streptozotocin-induced diabetes. Exp Ther Med. 2017;14(1):383-90.
DOI:10.3892/etm.2017.4475, PMID 28672943
15. Gasmi S. Classic labyrinth test for neurobehavioral evaluation in Wistar rats. Bio Protoc. 2018;8(18):e3007.
DOI: 10.21769/BioProtoc.3007, PMID 34395798
16. Radwan AM, Aboelfetoh EF, Kimura T, Mohamed TM, El-Keiy MM. Fenugreek-mediated synthesis of zinc oxide nanoparticles and evaluation of its *in vitro* and *In vivo* antitumor potency. Biomed Res Ther. 2021;8(8):4483-96.
DOI: 10.15419/bmrat.v8i8.687.
17. Tousson E, Beltagy DM, El-Gerbed MSA, Gazia MA, Akela MA. The ameliorating role of folic acid in rat hippocampus after propylthiouracil-induced hypothyroidism. Biomed Aging Pathol. 2012;2(3):104-10.
DOI: 10.1016/j.biomag.2012.07.004
18. Beltagy DM, Nawar NF, Mohamed TM, Tousson E, El-Keey MM. Beneficial consequences of probiotic on mitochondrial hippocampus in Alzheimer's disease. J Complement Integr Med. 2021; 18(4):761-7.
DOI:10.1515/jcim-2020-0156, PMID 33781011
19. Beltagy DM, Nawar NF, Mohamed TM, Tousson E, El-Keey MM. Beneficial consequences of probiotic on mitochondrial hippocampus in Alzheimer's disease. J Complement Integr Med. 2021;18(4):761-7.
DOI: 10.1515/jcim-2020-0156, PMID 33781011
20. Burns CM, Chen K, Kaszniak AW, Lee W, Alexander GE, Bandy D et al. Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions. Neurology. 2013;80(17):1557-64.
DOI:10.1212/WNL.0b013e31828f17de, PMID 23535495
21. Mohamed TM, Youssef MAM, Bakry AA, El-Keiy MM. Alzheimer's disease improved through the activity of mitochondrial chain complexes and their gene expression in rats by boswellic acid. Metab Brain Dis. 2021;36(2):255-64.
DOI: 10.1007/s11011-020-00639-7, PMID 33159653
22. Gillani SW, Ghayedi N, Roosta P, Seddigh P, Nasiri O. Effect of metformin on lipid profiles of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. J Pharm Bioallied Sci. 2021;13(1):76-82.
DOI: 10.4103/jpbs.JPBS_370_20, PMID 34084051
23. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):122.
DOI: 10.1186/s12933-018-0762-4, PMID 30170598
24. Torres LL, Quaglio NB, de Souza GT, Garcia RT, Dati LMM, Moreira WL et al. Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis. 2011;26(1):59-68.
DOI:10.3233/JAD-2011-110284, PMID 21593563
25. Greilberger J, Koidl C, Greilberger M, Lamprecht M, Schroecksnadel K, Leblhuber F et al. Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease. Free Radic Res. 2008;42(7):633-8. doi: 10.1080/10715760802255764, PMID 18654878.
26. Gustaw-Rothenberg K, Kowalczuk K, Stryjecka-Zimmer M. Lipids' peroxidation markers in Alzheimer's disease and vascular dementia. Geriatr Gerontol Int. 2010;10(2):161-6.
DOI: 10.1111/j.1447-0594.2009.00571.x, PMID 20446930
27. Patil SP, Jain PD, Ghumatkar PJ, Tambe R, Sathaye S. Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice. Neuroscience. 2014;277:747-54.
DOI: 10.1016/j.neuroscience.2014.07.046, PMID 25108167
28. Tang G, Yang H, Chen J, Shi M, Ge L, Ge X et al. Metformin ameliorates sepsis-

induced brain injury by inhibiting apoptosis, oxidative stress and neuroinflammation via the PI3K/Akt signaling pathway. Oncotarget. 2017;8(58):97977-89.
DOI: 10.18632/oncotarget.20105, PMID 29228667

29. Akinola O, Gabriel M, Suleiman A-A, Olorunsogbon F. Treatment of alloxan-induced diabetic rats with metformin or glitazones is associated with amelioration of hyperglycaemia and neuroprotection. TODIAJ. 2012;5(1):8-12.
DOI: 10.2174/1876524601205010008

30. Sangi SMA, Jalaud NAAl. Prevention and treatment of brain damage in streptozotocin induced diabetic rats with metformin, Nigella sativa, Zingiber officinale, and Punica granatum. Biomed Res Ther. 2019;6(7): 3274-85.
DOI: 10.15419/bmrat.v6i7.554

31. Pilipenko V, Narbute K, Pupure J, Langrate IK, Muceniece R, Kluša V. Neuroprotective potential of antihyperglycemic drug metformin in streptozocin-induced rat model of sporadic Alzheimer's disease. Eur J Pharmacol. 2020;881: 173290.
DOI: 10.1016/j.ejphar.2020.173290, PMID 32580040

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/95970